Tredegar (TG) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
25 Mar, 2026Executive summary
The 2026 annual meeting will be held virtually on May 8, 2026, with shareholders able to vote and ask questions online.
Shareholders will vote on electing seven directors, a non-binding advisory vote on executive compensation, and ratification of KPMG LLP as the independent auditor for 2026.
The Board recommends voting in favor of all proposals and highlights strong governance, annual director elections, and active risk oversight.
Voting matters and shareholder proposals
Proposals include election of seven directors, advisory vote on executive compensation, and ratification of KPMG LLP.
Shareholders can submit proposals and director nominations for future meetings, following specific bylaw requirements.
No shareholder proposals or nominations were received for the 2026 meeting.
Board of directors and corporate governance
Board consists of seven nominees with diverse backgrounds, 57% diverse representation, and an average tenure of six years.
Separate CEO and Chairman roles, majority independent directors, and annual board evaluations.
Committees include Audit, Executive Compensation, and Nominating and Governance, all comprised of independent directors.
Succession planning led to new CEO and CFO appointments effective January 1, 2026.
Latest events from Tredegar
- 2025 saw robust earnings growth, improved leverage, and strong segment performance amid tariff challenges.TG
Q4 202511 Mar 2026 - Virtual annual meeting to vote on directors, executive pay, and auditor, with strong governance focus.TG
Proxy Filing2 Dec 2025 - Virtual meeting on May 9, 2025, to vote on directors, pay, and auditor ratification.TG
Proxy Filing2 Dec 2025 - Q3 2025 delivered strong profit and EBITDA growth, led by Aluminum Extrusions and lower net debt.TG
Q3 20252 Dec 2025 - Net income and EBITDA fell in Q2 2025 as tariffs and inefficiencies pressured results.TG
Q2 20258 Oct 2025 - Improved Q3 results, Terphane sale, and lower leverage amid ongoing margin pressures.TG
Q3 202413 Jun 2025 - Q2 2024 net income rebounded to $8.8M with broad EBITDA gains and key regulatory decisions ahead.TG
Q2 202413 Jun 2025 - Net income jumped to $10.1M as Terphane sale and tariffs boosted results despite margin pressure.TG
Q1 20256 Jun 2025 - Tredegar posts strong EBITDA growth and sharp debt reduction, returning to profitability in 2024.TG
Q4 20245 Jun 2025